Trial Profile

Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS).

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sorafenib (Primary) ; Antineoplastics; Lenvatinib; Ramucirumab; Regorafenib
Indications Liver cancer
Focus Therapeutic Use
Acronyms TACTICS

Most Recent Events

17 Jan 2021 Primary endpoint (Overall Survival) has not been met as per results presented at the 2021 Gastrointestinal Cancers Symposium
17 Jan 2021 Results of Final overall survival analysis presented at the 2021 Gastrointestinal Cancers Symposium
04 Dec 2019 Results assessing efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib in patients with hepatocellular carcinoma, published in the Gut.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com